The draft guidance from this partial rapid review, published on 17 August 2023, recommends that access to nirmatrelvir plus ritonavir (Paxlovid ® ) is extended beyond the current cohort, to individuals aged 70 years and over, and those with diabetes, obesity (BMI of 35 kg/m 2 or more), or heart failure. If there are no appeals from key stakeholders, the f...